Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.
作者信息
Aghemo Alessio, Horsmans Yves, Bourgeois Stefan, Bondin Mark, Gschwantler Michael, Hofer Harald, Semmo Nasser, Negro Francesco, Zhang Zhenzhen, Marcinak John, Veitsman Ella, Hazzan Rawi, Mimidis Konstantinos, Goulis Ioannis, Marques Nuno, Flisiak Robert, Mazur Wlodzimierz, Roncero Carlos, Marra Fiona, Pageaux Georges Philippe, Asselah Tarik, Lampertico Pietro
机构信息
Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.
Division of Internal Medicine and Hepatology, Department of Gastroenterology, Humanitas Research Hospital IRCCS, Via A. Manzoni 56, 20089, Rozzano, Milan, Italy.
出版信息
Infect Dis Ther. 2021 Dec;10(4):2223-2225. doi: 10.1007/s40121-021-00529-0.
Abstract
摘要
相似文献
1
Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.对《接受格卡瑞韦/哌仑他韦治疗的慢性丙型肝炎感染历史上未得到充分治疗患者的真实世界结局》的勘误
Infect Dis Ther. 2021 Dec;10(4):2223-2225. doi: 10.1007/s40121-021-00529-0.
2
Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.glecaprevir/pibrentasvir治疗慢性丙型肝炎感染的历史上未得到充分治疗的患者的真实世界转归
Infect Dis Ther. 2021 Dec;10(4):2203-2222. doi: 10.1007/s40121-021-00455-1. Epub 2021 Jun 14.
3
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis.真实世界中 glecaprevir/pibrentasvir 治疗慢性丙型肝炎病毒感染患者的疗效和安全性：一项荟萃分析。
J Hepatol. 2020 Jun;72(6):1112-1121. doi: 10.1016/j.jhep.2020.01.025. Epub 2020 Feb 13.
4
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.8 周格卡瑞韦哌仑他韦在初治代偿期肝硬化患者中的真实世界临床应用
Adv Ther. 2020 Sep;37(9):4033-4042. doi: 10.1007/s12325-020-01449-0. Epub 2020 Aug 4.
5
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.真实世界中 glecaprevir/pibrentasvir 治疗慢性丙型肝炎感染的疗效和安全性：来自德国丙型肝炎注册研究的数据。
Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059. doi: 10.1111/apt.15222. Epub 2019 Mar 15.
6
Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).格卡瑞韦哌仑他韦治疗亚洲慢性丙型肝炎病毒感染：两项多中心、3 期研究-一项随机、双盲研究（VOYAGE-1）和一项开放标签、单臂研究（VOYAGE-2）。
Lancet Gastroenterol Hepatol. 2020 Sep;5(9):839-849. doi: 10.1016/S2468-1253(20)30086-8. Epub 2020 Jul 16.
7
Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.Glecaprevir/Pibrentasvir 治疗 8 或 12 周对无肝硬化的 2、4、5 或 6 型丙型肝炎病毒感染患者的疗效。
Clin Gastroenterol Hepatol. 2018 Mar;16(3):417-426. doi: 10.1016/j.cgh.2017.09.027. Epub 2017 Sep 22.
8
Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real-world data from the German Hepatitis C-Registry.格卡瑞韦/哌仑他韦在肝硬化丙型肝炎患者中安全有效：来自德国丙型肝炎注册中心的真实世界数据。
Liver Int. 2021 May;41(5):949-955. doi: 10.1111/liv.14829. Epub 2021 Mar 1.
9
Efficacy and safety of glecaprevir/pibrentasvir in treatment-naïve adults with chronic hepatitis C virus genotypes 1-6 in Brazil.在巴西，初治慢性丙型肝炎病毒 1-6 型成人患者中 glecaprevir/pibrentasvir 的疗效和安全性。
Ann Hepatol. 2021 Jan-Feb;20:100257. doi: 10.1016/j.aohep.2020.09.002. Epub 2020 Sep 17.
10
Effects of Renal Impairment and Hemodialysis on the Pharmacokinetics and Safety of the Glecaprevir and Pibrentasvir Combination in Hepatitis C Virus-Negative Subjects.肾功能损害和血液透析对丙型肝炎病毒阴性受试者中格卡瑞韦哌仑他韦联合制剂的药代动力学和安全性的影响。
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.01990-17. Print 2018 Mar.
引用本文的文献
1
Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.Glecaprevir/Pibrentasvir 治疗 8 周在挑战性 HCV 患者中的安全性和有效性：来自 CREST 研究的意大利数据。
PLoS One. 2023 Feb 2;18(2):e0280165. doi: 10.1371/journal.pone.0280165. eCollection 2023.
2
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study.使用 8 周格卡匹韦/哌仑他韦治疗初治代偿期肝硬化丙型肝炎病毒感染患者的安全性和有效性：CREST 研究。
Adv Ther. 2022 Jul;39(7):3146-3158. doi: 10.1007/s12325-022-02158-6. Epub 2022 May 11.
3
Therapeutic potential of pyrrole and pyrrolidine analogs: an update.吡咯和吡咯烷类似物的治疗潜力：最新研究进展。
Mol Divers. 2022 Oct;26(5):2915-2937. doi: 10.1007/s11030-022-10387-8. Epub 2022 Jan 25.
Zotero 插件